Business
Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Sir Andrew Witty, the former head of GlaxoSmithKline, current president of UnitedHealth Group and chief executive officer of Optum, is temporarily stepping away from his duties to co-lead a World Health Organization effort to combat COVID-19.
Gilead said that the Phase III trial for mild to moderate patients had been ended because of lack of patients to enroll.
Social distancing has become the new norm in the attempt to prevent the spread of COVID-19, and that norm could become a mainstay of life for the next couple years, a new study suggests.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 15, 2020.
Under the terms of the deal, Novartis is paying TScan an upfront technology access fee and research funding totaling $30 million.
Cerevance secured $45 million in a Series B financing round to support the development of its therapeutics for central nervous system diseases, including Alzheimer’s and Parkinson’s disease.
Origin, a 3D printing specialist for medical devices, just completed clinical trials and validation of its 3D-printed nasopharyngeal swabs for use in COVID-19 test kits. It is scaling up production and accepting orders to manufacture millions of the swabs.
The investigators assayed the levels and analyzed the expression patterns of more than 3,000 proteins in brain and cerebrospinal fluid samples collected at centers across the U.S.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
“Blackstone is uniquely positioned to provide customized, one-stop-shop financing solutions at scale while establishing development collaborations with the world’s leading biotech companies,” said Nicholas Galakatos, global head of Blackstone Life Sciences.